August 1, 2016 08:02 AM EDT
R&D

Bio­gen, Io­n­is de­clare an ear­ly vic­to­ry for PhI­II spinal mus­cu­lar at­ro­phy study, trig­ger­ing $75M pay­out

John Carroll

Editor & Founder

Two months af­ter a clin­i­cal hold on a top Phase III pro­gram tripped up Io­n­is and sent its shares in­to a tail­spin, the an­ti­sense RNA …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times